XML 34 R25.htm IDEA: XBRL DOCUMENT v3.25.1

Segment Disclosure (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Summary of Significant Expense related to the Life Science Segment

The table below summarizes segment net loss, including significant expenses for the three months ended March 31, 2025 and 2024 (in thousands):

		Three Months Ended March 31,
		2025				2024
Royalty revenue and sale of royalty rights		$	—			$	16,146
Costs and operating expenses
Cost of revenues			—				475
Research and development
Clinical product candidates			5,146				3,974
Clinical product manufacturing			3,384				2,563
Personnel-related expenses excluding stock-based compensation			4,739				3,504
Stock-based compensation			1,122				678
Depreciation and amortization			473				315
Other (i)			2,180				1,995
Total research and development expenses			17,044				13,029
General and administrative
Personnel-related expenses excluding stock-based compensation			1,491				1,918
Stock-based compensation			2,509				3,643
Professional and consultant fees			814				1,080
Other (ii)			1,056				1,606
Total general and administrative expenses			5,870				8,247
Total costs and operating expenses			22,914				21,751
Other segment income (iii)			1,756				2,349
Segment net loss		$	(21,158	)		$	(3,256	)
Reconciliation of profit or loss
Adjustments and reconciling items			—				—
Consolidated net loss		$	(21,158	)		$	(3,256	)

(i)Other research and development segment items include facilities expenses, lab services, professional services and technology costs.

(ii)Other general and administrative segment items include facilities expenses, technology costs, insurance and depreciation.

(iii)Other segment income for the three months ended March 31, 2025 and 2024 consisted of $1.2 million and $1.6 million of interest and investment income and $0.5 million and $0.8 million of sublease income, respectively.

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration